Lucence was delighted to participate in the ASCO Virtual Scientific Program 2020 organized by the American Society of Clinical Oncology from May 29 – 31 2020.
We presented data demonstrating high sensitivity of our liquid biopsy technology, AmpliMARK™, at a limit of detection of 0.1% variant allele frequency in detecting clinically relevant biomarkers in lung cancer, alongside promising data in breast and blood cancers.
In lung cancer, AmpliMARK™ achieved 97.4% concordance for recommended biomarkers between two orthogonal liquid biopsy platforms. Our technology also demonstrated high sensitivity in detecting mutations in PIK3CA alongside other driver genes, supporting its clinical utility in breast tumors. AmpliMARK™ was further extended and validated for ultrasensitive multiplex detection of structural rearrangements in ALK, RET, ROS1 and PD-L1 in solid and blood cancers.
Read more about these studies in the posters below.
Clinical utility of a liquid biopsy diagnostic approach in lung cancer using amplicon-based next-generation sequencing in parallel with allele-specific PCR
Authors: Yukti Choudhury, Wai Min Phyo, Jing Shan Lim, Chaitanya Gupta, Yiliang Ho, Carina Tay, Yuki Sim, Wei Shuen Ng, Michelle Pek, Min-Han Tan, Tan Min Chin, Yew Oo Tan, Seng Weng Wong, Victor Hsue, William Foo, Wing Kin Sze, Siu Kei AU and Tai Chung Lam
An ultrasensitive amplicon-based sequencing panel for non-invasive molecular testing of hematological malignancies using blood
Authors: Chae Yin Cher, Zi Yi Lim, Daryl Tan, Hae Tha Mya, Wichean Mongkonsritragoon, Min-Han Tan and Yukti Choudhury